Table 1.
Ongoing trials investigating poly (ADP-ribose) polymerase (PARP) inhibitors in TNBC.
| Phase | Clinical Trial | Treatment | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Phase 1 | A pilot study of Olaparib and Durvalumab in patients with metastatic triple negative breast cancer (TNBC) | Olaparib Durvalumab | NCT03544125 |
| Phase 1 | A phase I of Olaparib with Radiation Therapy in patients with inflammatory, loco-regional advanced or metastatic TNBC | Olaparib Radiation Therapy | NCT03109080 |
| Phase 1 | An open, non-randomized, multi-center Phase I study to access the safety and efficacy of Fluzoparib given in combination with Apatinib | Fluzoparib Apatinib | NCT03075462 |
| Phase 1 | A phase 1 study of PARP inhibitor Olaparib and HSP90 inhibitor AT13387 | Olaparib Onalespib | NCT02898207 |
| Phase 2 | A phase II open-label, randomized study of PARP inhibition either alone or in combination with anti-PD-L1 Therapy | Atezolizumab Olaparib | NCT02849496 |
| Phase 1 Phase 2 |
Phase 1/2 clinical study of Niraparib in combination with Pembrilizumab (MK-3475) | Niraparib Pembrolizumab | NCT02657889 |
| Phase 2 | A phase II clinical trial of the PARP inhibitor Talazoparib | Talazoparib Tosylate | NCT02401347 |